(OCX) FY2024Q2 Earning Prediction

08/08 04:00:00

After Hours

(OCX) is set to release its earnings performance on 08/08 04:00:00 in After Hours trading. Consensus forecasts predict a revenue of 312.37K and an earnings per share (EPS) of for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!

Estimate

Actual

Surprise

RevenueMISS

312.37K

104.00K

-66.71%

EPS-

AI Summary

Attend Webcast

Earnings Surprise Analysis

The chart displays the extent of earnings surprises and corresponding stock price movements for each earnings event.

Revenue

EPS

OCX Transcript

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

Unknown5-12

The earnings call reveals mixed signals. While there is optimism about the GraftAssure launch, partnership with Bio-Rad, and potential market expansion, concerns about clinical trial success, financial risks, and reliance on key customers temper this optimism. The Q&A section highlights enthusiasm from transplant centers but also exposes uncertainties in market adoption and competitive pressures. The negative cash flow and dependency on a single customer further contribute to a cautious outlook. Given these factors, a neutral stock price movement is expected over the next two weeks.

Earnings call transcript: OncoCyte’s Q1 2025 revenue beats expectations

Unknown5-12

The earnings call reveals a mixed outlook. The partnership with Bio-Rad and increased gross margins are positives, but the lower revenue guidance for Q2 and consistent cash burn are concerns. The Q&A section shows enthusiasm from transplant centers but also highlights uncertainties in market adoption and regulatory risks. Without a clear market cap, the stock might have a moderate reaction. Therefore, the overall sentiment is neutral, with no strong catalysts for significant stock price movement over the next two weeks.

OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript

Unknown3-25

The earnings call reveals significant financial instability with a large EPS miss, posing a strong negative sentiment. Although there are positive operational updates, such as market expansion and regulatory submissions, the Q&A highlights uncertainties and delays in FDA approvals. The lack of material revenue projection from the GraftAssure kits and unclear management responses further exacerbate concerns. Given the EPS miss and regulatory uncertainties, the stock price is likely to react negatively in the short term.

Earnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advances

Unknown3-24

The earnings call reflects a mixed outlook: strong financial management and promising future growth, but significant regulatory and competitive risks. The Q&A indicates cautious optimism with uncertainties around regulatory approval timelines and market adoption. Despite financial stability and shareholder commitment, the lack of immediate revenue from the RUO product and competitive pressures suggest a neutral impact on the stock price.

OCX Report

Frequently Asked Questions

What is the undefined FY2024Q2 Earnings Release Date and Time?

(OCX) is scheduled to release its FY2024Q2 earnings report onAug 8, 2024, After Hours(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.

What Are the Consensus Forecasts for undefined FY2024Q2 Revenue and EPS?

Analysts' consensus predicts 312.37K in revenue and an EPS of 0.00 for 's FY2024Q2.

What Does Intellectia's AI Predict for undefined FY2024Q2 Earnings?

Intellectia's exclusive AI algorithms forecast a for's FY2024Q2 earnings, with a prediction date of Aug 8, 2024.

How Can I Use This Earnings Prediction to Trade OCX Stock?

Leverage Intellectia's AI forecast to position trades ahead of theAug 8, 2024 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.

How Accurate Is Intellectia's AI for Earnings Predictions Like undefined FY2024Q2?

Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.

How does AI Earnings Prediction generate its forecasts?

AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!

When are the predictions available, and how often are they updated?

Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.

Can I use AI Earnings Prediction for all types of stocks?

Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!